Irving Institute Announces New Pilot Awards to Fund COVID-19 Research

May 26, 2020

The Irving Institute for Clinical and Translational Research, home to Columbia University’s Clinical and Translational Science Award (CTSA) Program hub, announces the winners of two rapid response pilot programs to fund COVID-19 research.

The Irving Institute Translational Therapeutics (TRx) Accelerator, the Herbert Irving Comprehensive Cancer Center (HICCC) Accelerating Cancer Therapeutics (ACT) and Biomedical Engineering’s BiomedX launched a special pilot program to support projects focused on translating a therapeutic for treatment of COVID-19 toward commercialization. The 2020 TRx COVID-19 pilot awardees are:

Development of Cidofiovir Prodrugs as Potential Orally Available Medication for COVID-19

  • Jingyue Ju, PhD, Chemical Engineering

Rapid Development of SARS-CoV-2 3CL Protease Inhibitors for treatment of COVID-19

  • Brent Stockwell, PhD, Biological Sciences

Adoptive Transfer of Coronavirus-specific T Cells for Prophylaxis and Immunotherapy of COVID-19

  • Pawel Muranski, MD, Medicine

In partnership with the HICCC, the Irving Institute is also supporting the following SARS-CoV-2 (COVID-19) Research pilot grantees:

Identification of adverse SARS-CoV-2 infection outcome determinants

  • Sagi Shapira, PhD, Systems Biology (in Microbiology and Immunology)

Novel technologies to identify SARS-CoV-2 therapeutics

  • Hee Yang, PhD, Pathology & Cell Biology

Smartphone-enabled home serology tests for large-scale, accurate, and trackable, COVID-19 testing and surveillance

  • Samuel K. Sia, PhD, Biomedical Engineering


We congratulate the awardees and are proud to support this timely research. View the Irving Institute's COVID-19 Research Initiative to learn more about how we are addressing the pandemic. 


Infectious Diseases, Campus News, Research, NIH/NCATS, Funding, COVID-19, Pilot Awards, Translational Therapeutics